9.81
+0.0945(+0.97%)
Currency In USD
| Previous Close | 9.72 |
| Open | 9.89 |
| Day High | 10.4 |
| Day Low | 9.77 |
| 52-Week High | 18.9 |
| 52-Week Low | 9.34 |
| Volume | 1.49M |
| Average Volume | 2.49M |
| Market Cap | 958.74M |
| PE | -20.45 |
| EPS | -0.48 |
| Moving Average 50 Days | 13.64 |
| Moving Average 200 Days | 13.49 |
| Change | 0.09 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $392.58 as of September 30, 2025 at a share price of $9.815. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 3 years ago, it would be worth $1,858.81 as of September 30, 2025 at a share price of $9.815.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire Inc.
Sep 19, 2025 12:00 PM GMT
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Ja
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-wo
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to a